Ensign Peak Advisors
CBAY

Ensign Peak Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Ensign Peak Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,700
Closed -$1.1M – 1767
2023
Q4 		$1.1M Buy
46,700
+5,450
+13% +$97.1K ﹤0.01% 1297
2023
Q3 		$615K Buy
+41,250
New +$547K ﹤0.01% 1519

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ensign Peak Advisors's CBAY Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 46,700 shares — an estimated $1.1M sold.

Ensign Peak Advisors first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $1.1M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 46,700 Cymabay Therapeutics shares in Q1 2024, an estimated $1.1M.
  • Ensign Peak Advisors first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
  • Ensign Peak Advisors's Cymabay Therapeutics position peaked at $1.1M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.